Watchdog calls for better end-of-life care at jail
A jail for sex offenders should have an end-of-life care centre, a watchdog report says.
The Independent Monitoring Board (IMB) has released its latest findings for HMP The Verne in Portland, Dorset.
The annual report revealed prison officers spent more than 13,000 hours on bed watch duties between 2023-24.
An end-of-life facility in the prison would help "given the ageing population" held in the prison, the report explained.
Oxleas NHS Foundation Trust is responsible for healthcare at the prison and has been contacted for comment.
The report highlights the "excellent, high-quality care" provided by Oxleas, but explained 33% of the 600 prisoners were over 60 years old.
It said: "A more elderly population means that many of the prisoners have complex health and social care needs. Some have multiple diagnoses of long-term or terminal illnesses."
The board said the current healthcare building is in a "deplorable state" and a new facility needs to be provided.
In September 2023, a 16-bed social care suite was opened in the prison, with care workers on shift 24 hours a day.
The board said the beds in this suite have been "fully occupied ever since the unit opened".
It continued: "Although the care suite is a most welcome addition to the prison, the board still feels that there should be a place for an end-of-life care suite that is staffed by a trained nurse 24 hours a day."
Figures included in the report show prison officers spent a total of 13,386 hours on bed watch and there had been six prisoner deaths in the report year.
A statement from The Verne IMB co-chairs said: "The board would welcome the provision of a dedicated end-of-life facility, which we feel would not only be a cost-effective addition to the existing provision, but provide sufficient care from appropriately trained medical staff to those with terminal illnesses."
You can follow BBC Dorset on Facebook, X, or Instagram.
Care of frail sex offenders not humane, says report
Sex offenders' behaviour not challenged at jail
Plans for extra prison places approved
Inmates need more purposeful activity, report says
Five prisoners died during Covid outbreak - report
The Verne Prison
Independent Monitoring Boards
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
MAHA, social media further complicating parenthood
(NewsNation) — New parents have always sought advice about whether to sleep train or use formula, but the 'Make America Healthy Again' movement has raised even more questions. Initiatives backed by Robert F. Kennedy Jr. have filled social media feeds with polarizing topics, including questions about raw milk, unmedicated childbirth, ultraprocessed foods and vaccinations. A national poll by C.S. Mott Children's Hospital found four out of five parents with young children — from newborn to 4 years old — use social media to discuss their concerns about a range of parenting topics. 'Agroterrorism' fungus could harm US crops, livestock: Scientist Holistic pediatrician Dr. Ana Maria Temple told NewsNation that parents can honor their own values and make sound choices — if they're able to filter out the filler they find online. Rather than following thousands of Facebook, Instagram and TikTok pages and driving 'yourself insane,' Temple recommends going 'back to finding a provider with clinical expertise that can sit and work with you.' But the divisiveness on these topics goes beyond social media — it's happening on the soccer field over post-game snacks, at kids' parties over the birthday treats served and even at schools over the cleaning products used in the classroom. Doctor: Texas junk food bill a step in the right direction Temple said to keep an open mind and avoid self-criticism when absorbing all of these different suggestions and views, both online and in person. One of the MAHA movement's most prominent thought leaders, Moms Across America founder Zen Honeycutt, suggested looking for tried-and-true options from other parents. 'Our moms have tried dozens of different ways to recover our children from their health issues, and they're sharing the ones that work the best,' Honeycutt said. 'And doesn't mean that it'll work for your child, but it's something that our mothers have tried.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Miami Herald
42 minutes ago
- Miami Herald
Women on Weight-Loss Drugs Warned of Surprise ‘Ozempic Babies'
Women taking popular weight-loss drugs have been urged to use effective contraception while taking the medication amid reports of a so-called "Ozempic babies" phenomenon. The advice was issued by the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA), an executive agency of the Department of Health and Social Care, on Thursday. Newsweek reached out to the U.S. Department of Health and Human Services for comment via email. Demand for weight-loss drugs, including GLP-1 medications such as Ozempic, Wegovy, and Mounjaro, has surged in the United States. In May 2024, a KFF Health Tracking Poll found that approximately 6 percent of American adults—about 15 million people—were using GLP-1 agonists such as Ozempic, either for diabetes treatment or weight loss. Some experts have cautioned that women should use effective contraception while taking these medications amid reports that they may be linked to an increase in unexpected pregnancies, The Guardian reported last May. The MHRA issued its alert after receiving 40 reports related to pregnancies while using "GLP-1 medicines," which are known by the brand names Ozempic, Mounjaro, Wegovy, Saxenda, and Victoza. Ozempic and Wegovy contain semaglutide, which mimics the GLP-1 hormone to increase insulin, slow digestion, and suppress appetite. Mounjaro contains tirzepatide, which acts on an additional hormone related to blood sugar and appetite control. The MHRA warned that Mounjaro may reduce the effectiveness of oral contraceptives in people who are overweight. It received 26 pregnancy-related reports for Mounjaro alone. "Therefore, those taking Mounjaro who are overweight and are using an oral form of contraception are advised to also use a non-oral form of contraception," the agency said. "This only applies to those taking Mounjaro and is especially important for the four weeks after starting Mounjaro and after any dose increase." Hundreds of women have shared personal accounts of unplanned pregnancies while using these medications in online groups, including the Facebook group "I got pregnant on Ozempic." "My ozempic baby...I see so many posts about ozempic and asking for "stories or side effects," but I never see anyone warning about pregnancy... lol," one woman shared on Facebook. "If you don't know, I got pregnant on ozempic and so many other women have too..I was on ozempic for 6 weeks & found out I was pregnant. I was so scared, google had me frightened I would miscarry because of the ozempic. I then came across a group called 'I got pregnant on ozempic'. I started reading all of these stories about women fighting infertility and getting pregnant on ozempic." The Food and Drug Administration has not yet issued similar advisories in the United States. MHRA Chief Safety Officer Dr. Alison Cave said: "Skinny jabs are medicines licensed to treat specific medical conditions and should not be used as aesthetic or cosmetic treatments. They are not a quick fix to lose weight, and have not been assessed to be safe when used in this way. "Our guidance offers patients a 'one stop shop' for our up-to-date advice on how to use these powerful medicines safely. "This guidance should not be used as a substitute to reading the patient information leaflet or having a conversation with a healthcare professional as part of the prescribing process." Dr. Ilana Ressler, a reproductive endocrinologist at Illume Fertility, told Interesting Engineering on May 22: "There is this phenomenon of Ozempic what I think what's happening is women who may not have been ovulating before with the improvements that the medication is bringing on, that might be helping them to ovulate more regularly and they might be more likely to conceive while on the medication than not—so it is recommended to avoid pregnancy while taking the medication." Dr. Zuri A. Murrell, in a video on X last year: "There is nothing magical about the medicine that's in Ozempic that helps you get pregnant. But what it does is that a lot of times, when people can't, it's because of a hormone weight imbalance. "And so, when you lose weight, and sometimes when you lose weight rapidly, the hormones and the new you aren't in concert. Or they really are in concert, and guess what can happen, pregnancy. "So, it's not the Ozempic itself, it is actually the balancing out of your hormones. That means that you've lost fat, and that the body actually for you is working like it should. So just remember, Ozempic is not something that somebody takes and 'I'm pregnant.' What it does do is cause your body and hormone level to be more in sync and more likely that you can." It remains unclear whether the FDA will follow the MHRA's lead in issuing similar warnings or guidance on contraception. Related Articles Therapist Asks Who Women 'Want To Be Skinny For'-Her Theory Is Eye-OpeningThe Good Life: Weight Loss Wins, But at What Cost?How Ozempic and Other GLP-1 Drugs Are Eating Away at Body PositivityGen Z Is Leading a New Weight Loss Trend: Ozempic Microdosing 2025 NEWSWEEK DIGITAL LLC.
Yahoo
an hour ago
- Yahoo
Global Virus Network Issues Scientific Guidance on New COVID-19 Variant NB.1.8.1 and Vaccine Protection
Scientific collaboration, accurate public communication, and continued investment in prevention tools are critical in navigating the evolving COVID-19 landscape TAMPA, Fla., June 05, 2025 (GLOBE NEWSWIRE) -- The Global Virus Network (GVN) is closely monitoring the emergence of a newly identified SARS-CoV-2 variant, NB.1.8.1, a sublineage of the Omicron family. This variant was first identified in January 2025 and has rapidly spread across Asia and into other regions, including parts of the United States. The World Health Organization (WHO) has designated NB.1.8.1 as a Variant Under Monitoring due to its increasing prevalence and potential public health implications. Based on current evidence, GVN advises vigilance, not alarm, and reinforces the critical role of vaccination in preventing severe disease and death. Similar to previous Omicron subvariants, NB.1.8.1 contains spike protein mutations associated with increased transmissibility. However, no evidence suggests that NB.1.8.1 causes more severe illness or significantly evades vaccine-induced or natural immunity. Early laboratory and clinical data indicate that updated COVID-19 vaccines, including bivalent and XBB-based boosters, protect against severe outcomes such as hospitalization and death. There is no evidence at this time that NB.1.8.1 causes more severe illness than previous variants. Breakthrough infections may occur, particularly among individuals with waning immunity or those who are unvaccinated. Nevertheless, vaccines remain highly effective in reducing serious illness and death. Antiviral treatments such as nirmatrelvir/ritonavir (Paxlovid) and remdesivir demonstrate efficacy against a range of Omicron subvariants, including BQ.1, BQ.1.1, and XBB.1.5. NB.1.8.1 has been linked to significant increases in COVID-19 cases across several countries. According to the WHO, as of May 18, 2025, the NB.1.8.1 variant has been identified in 22 countries, accounting for 10.7% of global SARS-CoV-2 sequences submitted to the Global Initiative on Sharing All Influenza Data (GISAID) during epidemiological week 17 (April 21–27, 2025). This marks a significant increase from 2.5% four weeks prior. As of June 4, 2025, India reported 4,302 active COVID-19 infections, with nearly 300 new cases recorded within the previous 24 hours. States such as Delhi, Uttar Pradesh, West Bengal, Gujarat, and especially Kerala have experienced a steady rise in cases. During the week of April 27 to May 3, 2025, nearly 6,000 individuals in Taiwan sought medical assistance at hospitals due to COVID-19-related symptoms. This marked a 78% increase from the previous week and represented the fourth consecutive week of rising case numbers. As of early June 2025, in the U.S., more than a dozen cases of the NB.1.8.1 subvariant have been identified in Washington State. The variant was first detected in the U.S. between late March and early April through routine screenings of international travelers at airports in California, Washington State, Virginia, and New York. Subsequent cases have been reported in Ohio, Rhode Island, and Hawaii. In the U.S., there have been about 300 deaths per week from COVID-19 in 2025 through May. Periodic summer surges are anticipated, consistent with seasonal patterns observed in previous years. GVN Supports the Following COVID-19 Vaccine Recommendations: Adults aged 65 and older, and individuals with underlying conditions, should receive an updated COVID-19 booster tailored to circulating variants. All individuals 6 months and older, including children and adolescents, are encouraged to stay current with vaccinations, especially ahead of the fall and winter respiratory seasons. Children 6 months to 17 years of age should receive an age-appropriate, updated COVID-19 vaccine dose if they have not already done so within the past year, as protection from earlier vaccines may wane over time. Pediatric vaccination helps prevent severe outcomes, including hospitalization and multisystem inflammatory syndrome in children (MIS-C). Pregnant individuals are strongly encouraged to stay current on COVID-19 vaccination. Vaccination during pregnancy reduces the risk of COVID-19 hospitalization in infants by 61% and protects newborns for up to six months after birth—an especially important window given the high rate of emergency department visits for COVID-19 among infants. Studies have consistently shown that infection during pregnancy increases the risk of preterm birth, miscarriage, fetal death, and long-term neurodevelopmental issues. No safety concerns have been identified regarding vaccination in pregnancy or neonatal outcomes. Those not receiving a COVID-19 booster in the past year should consult a healthcare provider about updated vaccine timing and eligibility. Co-administration of COVID-19 and influenza vaccines is recommended when appropriate. Side effects from both COVID-19 and influenza vaccines are rare, and the cost-benefit of vaccination is heavily in favor of vaccination. The principal benefits of vaccination are preventing severe disease, rather than preventing infection itself. The rapid global spread of NB.1.8.1 underscores the ongoing need for proactive surveillance, timely data sharing, and pandemic preparedness. The appearance of new variants is expected and does not signal a public health emergency. Instead, it is a call to action for continued scientific vigilance and proactive health measures. GVN reiterates that this is an opportunity to prepare, not a reason to panic. Scientific collaboration, accurate public communication, and continued investment in prevention tools will remain critical in navigating the evolving COVID-19 landscape. Media Contact: Nora Samaranayakensamaranayake@ About the Global Virus Network The Global Virus Network (GVN) is a worldwide coalition comprising 80+ Virology Centers of Excellence and Affiliates across 40+ countries, whose mission is to facilitate pandemic preparedness against viral pathogens and diseases that threaten public health globally. GVN advances knowledge of viruses through (i) data-driven research and solutions, (ii) fostering the next generation of virology leaders, and (iii) enhancing global resources for readiness and response to emerging viral threats. GVN provides the essential expertise required to discover and diagnose viruses that threaten public health, understand how such viruses spread illnesses, and facilitate the development of diagnostics, therapies, and treatments to combat them. GVN coordinates and collaborates with local, national, and international scientific institutions and government agencies to provide real-time virus informatics, surveillance, and response resources and strategies. GVN's pandemic preparedness mission is achieved by focusing on Education & Training, Qualitative & Quantitative Research, and Global Health Strategies & Solutions. The GVN is a non-profit 501(c)(3) organization. For more information, please visit in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
